Vimian Group AB (publ) (VIMIAN) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and welcome to Vimian's first quarter earnings call 2026. I'm Olle Taibach, Group CEO, and I will present the first quarter results together with our CFO, Carly Wansetterberg-Boudry. Q1 is always an active period for us at Vimian, with strong cadence of industry and client events. This provides an early read on customer sentiment, I get valuable feedback across our beef businesses, opportunities to engage with industry peers and so on. It's encouraging to see that the strong traffic booth, high engagement and the positive feedback I get from veterinarians from these events are also reflected in a strong start to the year with positive momentum across the group. Three out of four of our segments, specialty pharma, veterinary services and diagnostic, all deliver double-digit growth in the quarter, well ahead of global animal health market. We completed two acquisitions in the quarter, the diagnostic company Ivet in Italy and the innovative Danish clinic group Fauna. These two acquisitions will add in total around 10 million euros in annual revenues. This morning we also signed the acquisition of veterinary service business Vetsafe with revenues of 1.6 million euros. This marks the entrance into Ireland for our veterinary service segment. Our M&A pipeline going into 2026 is fruitful and we have a strong position as a natural home for ambitious entrepreneurs within animal health. Operational cash conversion remains strong in the quarter being above 70%. And on April 13th, we welcome Lutta Lundås, Tartun as head of Medtech, adding vast experiences running entrepreneurial businesses based out of the US. Turning into the quarterly numbers, we report 8% revenue growth and reached 116 million euros in revenues for the first quarter. We delivered strong...